Search
Ultragenyx Pharmaceutical Inc
RAREAdd to Watchlist
16.300USD
+0.200+1.24%
Close 11-02 16:00（ET）
1.61BMarket Cap
LossP/E TTM
Ultragenyx Pharmaceutical Inc (RARE) Stock Price Target & Forecast
Analyst Rating
Based on 20 analysts giving stock ratings to Ultragenyx Pharmaceutical Inc in the past month.
Buy
4 Strong Buy
7 Buy
9 Hold
0 Sell
0 Strong Sell
Target Price
25.737USD+49.63%
RARE Analyst Recommendation Trends
In the current month, RARE has received 7 Buy Ratings, 9 Hold Ratings, and 0 Sell Ratings. RARE average Analyst price target in the last month is 25.737.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
4
4
6
6
6
6
6
6
7
7
11
11
11
12
12
13
9
9
2
2
2
2
2
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
20
20
19
19
19
20
20
20
RARE Analyst Rating for Peer Comparison
Updated: Nov 1, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Biogen Inc
BIIB
10
17
10
1
0
38
Amgen Inc
AMGN
4
9
19
3
1
36
Vertex Pharmaceuticals Inc
VRTX
10
17
5
0
1
33
Eli Lilly and Co
LLY
10
19
3
1
0
33
Alnylam Pharmaceuticals Inc
ALNY
5
18
9
0
0
32
AbbVie Inc
ABBV
8
18
6
0
0
32
Merck & Co Inc
MRK
7
15
9
0
0
31
Neurocrine Biosciences Inc
NBIX
13
14
4
0
0
31
Bristol-Myers Squibb Co
BMY
5
6
18
1
0
30
Gilead Sciences Inc
GILD
7
18
5
0
0
30
Financial Forecasting
Based on analysts' estimates, RARE EPS is projected to reach -1.117 in FY2026Q3, following reported EPS of -0.903 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-1.09
-1.51
-1.22
-1.12
-0.74
Actual
-1.29
-1.84
-0.90
--
--
Surprise
-17.92%
-21.81%
+25.70%
--
--
FAQs
What is Ultragenyx Pharmaceutical Inc's expected revenue for the next quarter?
Ultragenyx Pharmaceutical Inc's expected revenue is 183.12M.
What is Ultragenyx Pharmaceutical Inc's price target?
Analysts forecast that Ultragenyx Pharmaceutical Inc's price target is USD 25.74, with the highest forecast at USD 39.00 and the lowest forecast at USD 16.00.
How have Ultragenyx Pharmaceutical IncRARE's recent earnings per share performed?
The market expectation was USD -0.90, while Ultragenyx Pharmaceutical IncRARE's earnings per share (EPS) for the previous quarter was USD -1.84. EPS for the next quarter is expected at USD -1.12.
What is the analyst rating for Ultragenyx Pharmaceutical Inc?
Based on the ratings of Ultragenyx Pharmaceutical Inc's stock from 20 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.